verona pharma merck - Search News

News

Merck, COPD and Verona

Associated Press News on MSN · 2d

Merck spends $10 billion for Verona, gaining access to its COPD medication

Pharmaceutical giant Merck is buying Verona Pharma, a company that concentrates its efforts on respiratory diseases, in an approximately $10 billion deal.

MarketWatch on MSN · 2d

Merck dives into COPD treatments with $10 billion purchase of Verona Pharma

Merck & Co. Inc. is acquiring Verona Pharma PLC in a $10 billion deal that will expand the pharmaceutical giant’s portfolio of chronic obstructive pulmonary disease treatments with Verona Pharma’s Ohtuvayre.

Investopedia on MSN · 2d

Verona Pharma Stock Soars to All-Time High as Merck Buys Firm for $10B

Merck said the deal is valued at $107 per ADS, a 23% premium to Verona’s closing price yesterday.

21h

Merck's Verona Acquisition: Plugging A $4B Hole In A $20B Gap

Merck’s recent acquisition announcement sends a strong signal regarding its urgency to tackle the impending Keytruda patent ...

2don MSN

Merck to Buy Verona Pharma in $10 Billion Deal

The move bolsters Merck’s lineup as it braces for the 2028 loss of patent exclusivity for blockbuster cancer drug Keytruda.

BioPharma Dive17h

With Verona deal, Merck wagers on strength of lung drug’s patents

The main patent for Ohtuvayre, the COPD drug at the heart of Verona’s $10 billion sale, expired in 2020. For Merck to make ...

2don MSN

Merck nears about $10 billion deal for London-based lung therapy firm Verona, FT reports

U.S. drugmaker Merck is nearing a deal worth about $10 billion to buy Verona Pharma, a company focused on therapies for lung ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results